Featured Research

from universities, journals, and other organizations

Pneumococcal vaccine offers protection to HIV-infected African adults in clinical trial

Date:
April 4, 2010
Source:
Wellcome Trust
Summary:
A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa. The trials, conducted in Malawi, studied the efficacy of a vaccine against infection with the Streptococcus pneumoniae bacteria.

A clinical trial of a vaccine against a major cause of pneumonia and meningitis has shown that it can prevent three out of four cases of re-infection in HIV-infected adults in Africa.

Related Articles


The trials, conducted in Malawi and funded by the Wellcome Trust, studied the efficacy of a vaccine against infection with the Streptococcus pneumoniae bacteria. These bacteria are a primary cause of pneumonia and when they invade the blood stream and brain -- so called invasive pneumococcal disease (IPD) -- they cause the serious and often fatal illnesses of septicaemia and meningitis. In HIV-infected adults, particularly in sub-Saharan Africa, the risk of developing IPD increases between thirty and a hundred-fold.

The pneumococcal polysaccharide vaccine (PPV), which is currently used to protect adults in the UK and US, has been shown to have limited efficacy in HIV-infected adults and is not recommended in Africa.

Polysaccharide vaccines consist of long chains of sugar molecules isolated from the infectious agent (in this case, the pneumococcal bacteria). To enhance the vaccine's ability to elicit protective immunity, the sugar molecules can be bound to a 'carrier' protein which magnifies the immune response to the antigen -- such vaccines are known as conjugate vaccines.

Researchers at the Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine in Blantyre, Malawi, tested the efficacy of Prevnar, a pneumococcal conjugate vaccine (PCV) developed by pharmaceutical company Wyeth, in a double-blind randomized placebo-controlled clinical efficacy trial. The results are published in the New England Journal of Medicine.

The trial, led by Dr Neil French, formerly at the Liverpool school of Tropical Medicine, tested the vaccine on almost five hundred predominantly HIV-infected adults who recovered from IPD after being admitted to the Queen Elizabeth Central Hospital in Blantyre. They found that the vaccine prevented 74% of recurrent cases of IPD in patients with underlying HIV infection.

"This is the first trial to use a conjugate pneumococcal vaccine in an adult group and find clinical benefits," explains Dr French, who is now based at the London school of Hygiene and Tropical Medicine.

Of particular note was the fact that the vaccine prevented disease even when given to patients with CD4 counts of below 200 cells per cubic millimetre of blood. CD4 cells are an essential part of the immune system, but are targeted and destroyed by HIV. An HIV-infected person with a CD4 count below 200 is considered to have AIDS. This is the first time a conjugate vaccine has been effective at generating a protective response at low CD4 counts.

"The vaccine's efficacy at low CD4 counts is remarkable," says Dr French. "The general view on the use of any vaccines in HIV is that low CD4 counts make the vaccine useless. We've shown that conjugate technology overcomes the profound immune deficiency at these low counts. This gives hope for the possible use of conjugate technology in other vaccines targeting important HIV associated bacterial infections, most notably non-typhoidal Salmonella."

Dr French believes the study suggests that the conjugate pneumococcal vaccine may be applicable for use in other adults groups at risk of IPD.

"Since it works in patients with HIV infection, then by extension, it is likely to work in other adult groups, including the elderly and other at risk groups," he says. "This is an important finding to support the further development and use of conjugate vaccines for adults in general."

However, according to Dr French, the cost of the conjugate vaccines (around US$40 per dose) means that financing mechanisms akin to those available for paediatric vaccines through GAVI (Global Access to Vaccines Initiative) or other forms of subsidy will be needed to make these vaccines widely available to adults within Africa.


Story Source:

The above story is based on materials provided by Wellcome Trust. Note: Materials may be edited for content and length.


Journal Reference:

  1. French, Neil, Gordon, Stephen B., Mwalukomo, Thandie, White, Sarah A., Mwafulirwa, Gershom, Longwe, Herbert, Mwaiponya, Martin, Zijlstra, Eduard E., Molyneux, Malcolm E., Gilks, Charles F. A Trial of a 7-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults. New England Journal of Medicine, 2010; 362: 812-822 [link]

Cite This Page:

Wellcome Trust. "Pneumococcal vaccine offers protection to HIV-infected African adults in clinical trial." ScienceDaily. ScienceDaily, 4 April 2010. <www.sciencedaily.com/releases/2010/03/100303192436.htm>.
Wellcome Trust. (2010, April 4). Pneumococcal vaccine offers protection to HIV-infected African adults in clinical trial. ScienceDaily. Retrieved March 28, 2015 from www.sciencedaily.com/releases/2010/03/100303192436.htm
Wellcome Trust. "Pneumococcal vaccine offers protection to HIV-infected African adults in clinical trial." ScienceDaily. www.sciencedaily.com/releases/2010/03/100303192436.htm (accessed March 28, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, March 28, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com
WH Plan to Fight Antibiotic-Resistant Germs

WH Plan to Fight Antibiotic-Resistant Germs

AP (Mar. 27, 2015) — The White House on Friday announced a five-year plan to fight the threat posed by antibiotic-resistant bacteria amid fears that once-treatable germs could become deadly. (March 27) Video provided by AP
Powered by NewsLook.com
House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) — In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins